About Event

Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2023 event, please get in touch at info@hansonwade.com

In the last 18-24 months, catapulted by the urgency and opportunity to treat more homogenous COVID patient populations, the ARDS drug development field has spiked. As stakeholders with pipeline MScs, inflammation, and respiratory expand into ARDS, now is the time to finally advance therapeutics for this indication beyond the historical challenges, and harness the urgency and opportunity of a large unmet patient need 

The 2nd ARDS Drug Development Summit is the only industry-led meeting bringing together 80+ biopharma, pharmaceutical, and academic thought leaders dedicated to understanding and addressing acute respiratory distress syndrome.

With conversations covering early endpoints in clinical trials to benchmark, troubleshoot, and confidently verify proof of concept; get up to date on the hottest ARDS research, and network with leaders at this exclusive industry-specific conference. Spanning 3 days of thought-provoking content, leave this meeting with the actionable insights you need to supercharge your drug development

Access the full event guide here to see the agenda and speaker faculty.

Top Takeaways

Navigate the complexity of patient pathways in ARDS clinical trial design to achieve well-controlled, successful studies with Biomarck Pharmaceuticals, Edesa Biotech, and Tetra Biopharma
Illuminate multi-modal, practical, ARDS phenotyping to develop innovative ARDS precision therapies with Washington University, Harvard Medical School, and Amsterdam UMC
Explore the similarities and differences between COVID-19 ARDS and Non-COVID ARDS and explore lessons learned from the past couple of years to consolidate fundamental understandings of the disease to revolutionize drug development with Apeptico, Augusta University, Partner Therapeutics, and Virginia University
Leveraging the experiences of the ARDS drug development landscape to unlock novel therapeutic modalities that mirror the heterogeneity of ARDS patients with Healios K.K., Gen1E Life Sciences, and Aptarion Biotech

Why Join


  • Fast-track your disease knowledge
  • Expand your pipeline
  • Establish alliances with industry pioneers


Learn More

Pioneering Biotech

  • Showcase your work to the community
  • Access the latest research insights
  • Meet like-minded peers facing common challenges

Learn More

Academics & Clinicians

  • Meet senior leaders in this growing community
  • Contrast your disease knowledge with real-life applications
  • Explore the latest advances in the space

Learn More

Service Providers

  • Demonstrate how your expert solutions can help the industry
  • Be in front of an engaged audience in need of trusted partners
  • Network with 60+ senior experts in the respiratory space

Learn More

Who attends?

whos attending